Mountain Pacific Investment Advisers Inc. ID Cuts Stake in Thermo Fisher Scientific Inc (TMO)

Mountain Pacific Investment Advisers Inc. ID lessened its position in shares of Thermo Fisher Scientific Inc (NYSE:TMO) by 2.7% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 66,405 shares of the medical research company’s stock after selling 1,875 shares during the quarter. Mountain Pacific Investment Advisers Inc. ID’s holdings in Thermo Fisher Scientific were worth $12,564,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of TMO. Cibc World Markets Corp lifted its stake in Thermo Fisher Scientific by 6.9% in the first quarter. Cibc World Markets Corp now owns 210,776 shares of the medical research company’s stock valued at $32,375,000 after buying an additional 13,660 shares during the period. Patton Albertson Miller Group LLC lifted its stake in Thermo Fisher Scientific by 5.7% in the first quarter. Patton Albertson Miller Group LLC now owns 8,319 shares of the medical research company’s stock valued at $1,432,000 after buying an additional 449 shares during the period. Mastrapasqua Asset Management Inc. lifted its stake in Thermo Fisher Scientific by 2.8% in the first quarter. Mastrapasqua Asset Management Inc. now owns 39,056 shares of the medical research company’s stock valued at $5,999,000 after buying an additional 1,057 shares during the period. Dynamic Technology Lab Private Ltd acquired a new position in Thermo Fisher Scientific in the first quarter valued at about $1,167,000. Finally, Tredje AP fonden lifted its stake in Thermo Fisher Scientific by 11.2% in the first quarter. Tredje AP fonden now owns 43,773 shares of the medical research company’s stock valued at $6,730,000 after buying an additional 4,406 shares during the period. 83.78% of the stock is currently owned by institutional investors and hedge funds.

In other Thermo Fisher Scientific news, VP Seth H. Hoogasian sold 4,140 shares of the firm’s stock in a transaction that occurred on Monday, August 28th. The stock was sold at an average price of $177.80, for a total value of $736,092.00. Following the completion of the transaction, the vice president now directly owns 25,518 shares in the company, valued at $4,537,100.40. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, VP Peter E. Hornstra sold 3,894 shares of the firm’s stock in a transaction that occurred on Tuesday, September 5th. The shares were sold at an average price of $185.18, for a total value of $721,090.92. Following the completion of the transaction, the vice president now owns 19,751 shares of the company’s stock, valued at $3,657,490.18. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 22,738 shares of company stock valued at $4,021,512. 0.49% of the stock is owned by corporate insiders.

Thermo Fisher Scientific Inc (NYSE TMO) opened at $189.08 on Wednesday. The company has a current ratio of 1.26, a quick ratio of 0.81 and a debt-to-equity ratio of 0.85. The stock has a market capitalization of $75,471.34, a PE ratio of 20.68, a P/E/G ratio of 1.72 and a beta of 1.08. Thermo Fisher Scientific Inc has a fifty-two week low of $139.07 and a fifty-two week high of $201.20.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Wednesday, October 25th. The medical research company reported $2.31 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.24 by $0.07. The business had revenue of $5.12 billion during the quarter, compared to the consensus estimate of $5.03 billion. Thermo Fisher Scientific had a return on equity of 15.94% and a net margin of 11.73%. Thermo Fisher Scientific’s quarterly revenue was up 13.9% on a year-over-year basis. During the same period last year, the company earned $2.03 earnings per share. analysts anticipate that Thermo Fisher Scientific Inc will post 9.36 EPS for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Monday, January 15th. Investors of record on Friday, December 15th will be issued a dividend of $0.15 per share. The ex-dividend date of this dividend is Thursday, December 14th. This represents a $0.60 dividend on an annualized basis and a dividend yield of 0.32%. Thermo Fisher Scientific’s payout ratio is presently 10.19%.

TRADEMARK VIOLATION WARNING: “Mountain Pacific Investment Advisers Inc. ID Cuts Stake in Thermo Fisher Scientific Inc (TMO)” was published by Week Herald and is the property of of Week Herald. If you are reading this piece of content on another domain, it was illegally copied and republished in violation of international copyright & trademark law. The legal version of this piece of content can be read at https://weekherald.com/2017/11/15/mountain-pacific-investment-advisers-inc-id-cuts-stake-in-thermo-fisher-scientific-inc-tmo.html.

Several equities research analysts have issued reports on TMO shares. Leerink Swann increased their price target on Thermo Fisher Scientific from $190.00 to $207.00 and gave the stock an “outperform” rating in a report on Monday, October 9th. Zacks Investment Research upgraded Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $212.00 price target for the company in a report on Thursday, September 21st. Bank of America Corporation restated a “buy” rating and issued a $210.00 price target (up from $200.00) on shares of Thermo Fisher Scientific in a report on Friday, July 21st. Cowen and Company restated an “outperform” rating and issued a $220.00 price target (up from $200.00) on shares of Thermo Fisher Scientific in a report on Sunday, September 10th. Finally, Deutsche Bank AG set a $226.00 price target on Thermo Fisher Scientific and gave the stock a “buy” rating in a report on Thursday, October 26th. One research analyst has rated the stock with a hold rating and sixteen have given a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $205.71.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply